Predictors of survival following relapse or progression of small cell lung cancer: Southwest Oncology Group study 8605 report and analysis of recurrent disease data base

K. S. Albain, J. J. Crowley, L. Hutchins, David R Gandara, R. M. O'Bryan, D. D. Von Hoff, B. Griffin, R. B. Livingston

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Background. Survival after relapse or progression of small cell lung cancer (SCLC) is poor. The Southwest Oncology Group (SWOG) initiated a study of modulation of cyclophosphamide (Cy) resistance in this population. At study closure, the value of testing new regimens in previously treated patients was being debated nationally: Is there an independent impact of treatment over favorable prognostic factors? Thus, the authors analyzed the SWOG recurrent SCLC data base. Methods. A 12-hour infusion of cytosine arabinoside (ara-C) was used as a potential repair inhibitor of Cy-induced DNA damage in patients with relapsed SCLC. A data base of successive SWOG studies in recurrent SCLC was formed. The independent contribution to survival of prognostic factors, type of prior chemotherapy (CT), time from diagnosis, and type of CT on relapse were then assessed. Results. There were 3 partial responses observed in 67 patients, with substantial myelotoxicity. The median survival was 2.5 months, and 16% lived beyond 6 months. The multivariate analysis of the recurrent SCLC data base found that a normal lactate dehydrogenase (LDH) and second-line treatment with etoposide plus cisplatin (EP), if not initially treated with either alternating or complex multidrug regimens, were the only independent predictors of improved survival. The 2-year survival of this subset was 20%. Conclusions. The Cy/ara-C program cannot be recommended for patients with recurrent SCLC. However, EP independently contributed to improved survival in patients without complex prior CT and a normal LDH. This finding supports future trials of new approaches in certain subsets of SCLC patients with limited prior treatment.

Original languageEnglish (US)
Pages (from-to)1184-1191
Number of pages8
JournalCancer
Volume72
Issue number4
StatePublished - 1993

Fingerprint

Small Cell Lung Carcinoma
Databases
Recurrence
Survival
Cytarabine
Cyclophosphamide
Etoposide
L-Lactate Dehydrogenase
Drug Therapy
Cisplatin
DNA Damage
Therapeutics
Multivariate Analysis
Population

Keywords

  • cyclophosphamide plus ara-C
  • recurrent or relapsed disease
  • resistance modulation
  • small cell lung cancer
  • survival predictors

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Albain, K. S., Crowley, J. J., Hutchins, L., Gandara, D. R., O'Bryan, R. M., Von Hoff, D. D., ... Livingston, R. B. (1993). Predictors of survival following relapse or progression of small cell lung cancer: Southwest Oncology Group study 8605 report and analysis of recurrent disease data base. Cancer, 72(4), 1184-1191.

Predictors of survival following relapse or progression of small cell lung cancer : Southwest Oncology Group study 8605 report and analysis of recurrent disease data base. / Albain, K. S.; Crowley, J. J.; Hutchins, L.; Gandara, David R; O'Bryan, R. M.; Von Hoff, D. D.; Griffin, B.; Livingston, R. B.

In: Cancer, Vol. 72, No. 4, 1993, p. 1184-1191.

Research output: Contribution to journalArticle

Albain, KS, Crowley, JJ, Hutchins, L, Gandara, DR, O'Bryan, RM, Von Hoff, DD, Griffin, B & Livingston, RB 1993, 'Predictors of survival following relapse or progression of small cell lung cancer: Southwest Oncology Group study 8605 report and analysis of recurrent disease data base', Cancer, vol. 72, no. 4, pp. 1184-1191.
Albain, K. S. ; Crowley, J. J. ; Hutchins, L. ; Gandara, David R ; O'Bryan, R. M. ; Von Hoff, D. D. ; Griffin, B. ; Livingston, R. B. / Predictors of survival following relapse or progression of small cell lung cancer : Southwest Oncology Group study 8605 report and analysis of recurrent disease data base. In: Cancer. 1993 ; Vol. 72, No. 4. pp. 1184-1191.
@article{68900b40253b4316bdfdef274f8fc680,
title = "Predictors of survival following relapse or progression of small cell lung cancer: Southwest Oncology Group study 8605 report and analysis of recurrent disease data base",
abstract = "Background. Survival after relapse or progression of small cell lung cancer (SCLC) is poor. The Southwest Oncology Group (SWOG) initiated a study of modulation of cyclophosphamide (Cy) resistance in this population. At study closure, the value of testing new regimens in previously treated patients was being debated nationally: Is there an independent impact of treatment over favorable prognostic factors? Thus, the authors analyzed the SWOG recurrent SCLC data base. Methods. A 12-hour infusion of cytosine arabinoside (ara-C) was used as a potential repair inhibitor of Cy-induced DNA damage in patients with relapsed SCLC. A data base of successive SWOG studies in recurrent SCLC was formed. The independent contribution to survival of prognostic factors, type of prior chemotherapy (CT), time from diagnosis, and type of CT on relapse were then assessed. Results. There were 3 partial responses observed in 67 patients, with substantial myelotoxicity. The median survival was 2.5 months, and 16{\%} lived beyond 6 months. The multivariate analysis of the recurrent SCLC data base found that a normal lactate dehydrogenase (LDH) and second-line treatment with etoposide plus cisplatin (EP), if not initially treated with either alternating or complex multidrug regimens, were the only independent predictors of improved survival. The 2-year survival of this subset was 20{\%}. Conclusions. The Cy/ara-C program cannot be recommended for patients with recurrent SCLC. However, EP independently contributed to improved survival in patients without complex prior CT and a normal LDH. This finding supports future trials of new approaches in certain subsets of SCLC patients with limited prior treatment.",
keywords = "cyclophosphamide plus ara-C, recurrent or relapsed disease, resistance modulation, small cell lung cancer, survival predictors",
author = "Albain, {K. S.} and Crowley, {J. J.} and L. Hutchins and Gandara, {David R} and O'Bryan, {R. M.} and {Von Hoff}, {D. D.} and B. Griffin and Livingston, {R. B.}",
year = "1993",
language = "English (US)",
volume = "72",
pages = "1184--1191",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

TY - JOUR

T1 - Predictors of survival following relapse or progression of small cell lung cancer

T2 - Southwest Oncology Group study 8605 report and analysis of recurrent disease data base

AU - Albain, K. S.

AU - Crowley, J. J.

AU - Hutchins, L.

AU - Gandara, David R

AU - O'Bryan, R. M.

AU - Von Hoff, D. D.

AU - Griffin, B.

AU - Livingston, R. B.

PY - 1993

Y1 - 1993

N2 - Background. Survival after relapse or progression of small cell lung cancer (SCLC) is poor. The Southwest Oncology Group (SWOG) initiated a study of modulation of cyclophosphamide (Cy) resistance in this population. At study closure, the value of testing new regimens in previously treated patients was being debated nationally: Is there an independent impact of treatment over favorable prognostic factors? Thus, the authors analyzed the SWOG recurrent SCLC data base. Methods. A 12-hour infusion of cytosine arabinoside (ara-C) was used as a potential repair inhibitor of Cy-induced DNA damage in patients with relapsed SCLC. A data base of successive SWOG studies in recurrent SCLC was formed. The independent contribution to survival of prognostic factors, type of prior chemotherapy (CT), time from diagnosis, and type of CT on relapse were then assessed. Results. There were 3 partial responses observed in 67 patients, with substantial myelotoxicity. The median survival was 2.5 months, and 16% lived beyond 6 months. The multivariate analysis of the recurrent SCLC data base found that a normal lactate dehydrogenase (LDH) and second-line treatment with etoposide plus cisplatin (EP), if not initially treated with either alternating or complex multidrug regimens, were the only independent predictors of improved survival. The 2-year survival of this subset was 20%. Conclusions. The Cy/ara-C program cannot be recommended for patients with recurrent SCLC. However, EP independently contributed to improved survival in patients without complex prior CT and a normal LDH. This finding supports future trials of new approaches in certain subsets of SCLC patients with limited prior treatment.

AB - Background. Survival after relapse or progression of small cell lung cancer (SCLC) is poor. The Southwest Oncology Group (SWOG) initiated a study of modulation of cyclophosphamide (Cy) resistance in this population. At study closure, the value of testing new regimens in previously treated patients was being debated nationally: Is there an independent impact of treatment over favorable prognostic factors? Thus, the authors analyzed the SWOG recurrent SCLC data base. Methods. A 12-hour infusion of cytosine arabinoside (ara-C) was used as a potential repair inhibitor of Cy-induced DNA damage in patients with relapsed SCLC. A data base of successive SWOG studies in recurrent SCLC was formed. The independent contribution to survival of prognostic factors, type of prior chemotherapy (CT), time from diagnosis, and type of CT on relapse were then assessed. Results. There were 3 partial responses observed in 67 patients, with substantial myelotoxicity. The median survival was 2.5 months, and 16% lived beyond 6 months. The multivariate analysis of the recurrent SCLC data base found that a normal lactate dehydrogenase (LDH) and second-line treatment with etoposide plus cisplatin (EP), if not initially treated with either alternating or complex multidrug regimens, were the only independent predictors of improved survival. The 2-year survival of this subset was 20%. Conclusions. The Cy/ara-C program cannot be recommended for patients with recurrent SCLC. However, EP independently contributed to improved survival in patients without complex prior CT and a normal LDH. This finding supports future trials of new approaches in certain subsets of SCLC patients with limited prior treatment.

KW - cyclophosphamide plus ara-C

KW - recurrent or relapsed disease

KW - resistance modulation

KW - small cell lung cancer

KW - survival predictors

UR - http://www.scopus.com/inward/record.url?scp=0027162262&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027162262&partnerID=8YFLogxK

M3 - Article

C2 - 8393365

AN - SCOPUS:0027162262

VL - 72

SP - 1184

EP - 1191

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 4

ER -